Oncolytics Biotech Inc.
(MENAFN- Baystreet) 02:20 PM EST - Oncolytics Biotech Inc. : Announced an update on the proposed design of its planned registration-directed clinical trial in first-line pancreatic ductal adenocarcinoma (PDAC). The Company is currently scheduled to meet with the U.S. Food and Drug Administration (FDA) in mid-November 2025 to advance study details. Oncolytics Biotech Inc.
shares N are trading up 15 cents at $1.44.
Full Press Release:
Legal Disclaimer:
MENAFN provides the
information “as is” without warranty of any kind. We do not accept
any responsibility or liability for the accuracy, content, images,
videos, licenses, completeness, legality, or reliability of the information
contained in this article. If you have any complaints or copyright
issues related to this article, kindly contact the provider above.
Most popular stories
Market Research
- Seoul Exchange, One Of Only Two Licensed Platforms For Unlisted Securities, Will Exclusively Use Story To Settle Tokenized Rwas
- Phase 6 Reaches 50% Mark As Mutuum Finance (MUTM) Approaches Next Price Step
- 0G Labs Launches Aristotle Mainnet With Largest Day-One Ecosystem For Decentralized AI
- Solotto Launches As Solana's First-Ever Community-Powered On-Chain Lottery
- Kintsu Launches Shype On Hyperliquid
- Blockchainfx Raises $7.24M In Presale As First Multi-Asset Super App Connecting Crypto, Stocks, And Forex Goes Live In Beta
More Story
Comments
No comment